Ziopharm Oncology Inc (ZIOP) 10.81 $ZIOP
Today's Dead Cat Bounce Stock: ZIOPHARM Oncology (ZIOP)
at The Street - Tue Apr 21, 9:47AM CDT
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate
ZIOP: 10.81 (-0.39)
TissueGene, Inc. Hires Robert Newman as Chief Operating Officer
PR Newswire - Tue Apr 21, 8:25AM CDT
TissueGene, Inc. a clinical-stage biopharmaceutical company focused on developing novel regenerative therapies in the field of cell therapy, today announced the appointment of Robert A Newman to the position of Chief Operating Officer. Mr. Newman was most recently Senior Vice President, Manufacturing, Program Management & Clinical Operations at ZIOPHARM Oncology, a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies in the cancer treatment field. Mr. Newman is an accomplished bio-pharmaceutical executive who will oversee clinical operations, manufacturing, research & development, business development and regulatory affairs as TissueGene enters pivotal phase 3 trials for its lead cell-based gene therapy asset, TG-C for the treatment of late-stage osteoarthritis of the knee.
ZIOP: 10.81 (-0.39)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.81 (-0.39), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Ziopharm Oncology (ZIOP) Stock Falls Today on Mediocre Solid Tumor Therapy Data
at The Street - Mon Apr 20, 2:18PM CDT
Shares of Ziopharm Oncology (ZIOP) were down in afternoon trading Monday after so-called CAR-T cellular therapies for solid tumors showed mediocre results at a conference on Sunday.
ZIOP: 10.81 (-0.39)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06)
Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 81.59 (+0.36), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), LMT: 195.37 (-1.83), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), PBR: 9.99 (+0.59), RDS.B: 63.67 (-0.07), RDS.A: 62.76 (-0.20), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), NAO: 9.77 (-0.26), OA: 72.91 (-1.33), RGR: 56.18 (-0.03), UNP: 107.51 (-0.61), STO: 19.88 (+0.02)
Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm
at The Street - Thu Apr 02, 4:57AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ZIOP: 10.81 (-0.39), NWBO: 8.47 (-0.15), XON: 44.10 (-0.91)
Global Small Cell Lung Cancer Therapeutics Market 2015-2019 with Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi & ZIOPHARM Oncology Dominating
PR Newswire Europe - Wed Apr 01, 1:02PM CDT
DUBLIN, April 1, 2015 /PRNewswire/ --
ZIOP: 10.81 (-0.39), GSK: 46.59 (+0.28), BMY: 65.80 (-0.20)
ZIOPHARM Oncology (ZIOP) Highlighted As Weak On High Volume
at The Street - Wed Apr 01, 9:02AM CDT
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a weak on high relative volume candidate
ZIOP: 10.81 (-0.39)
Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 5:26PM CDT
Intrexon Corporation (XON) and Merck KGaA announced the signing of an agreement to develop and commercialize cancer therapies based on CAR-T platform.
CYTK: 7.25 (-0.18), ZIOP: 10.81 (-0.39), XON: 44.10 (-0.91)
Global Small Cell Lung Cancer Therapeutics Market 2015-2019
M2 - Tue Mar 31, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9z3pb/global_small_cell) has announced the addition of the "Global Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.6% over the period 2014-2019 The report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The strategic alliances among vendors are an important trend being witnessed in the market. These are expected to give these market players a competitive edge over the others. The companies can leverage their strengths, which is expected to prove mutually beneficial. According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Small cell lung cancer advances very fast, and the detection rate is low at the localized stage. Current treatment options cannot cure the disease; hence, the mortality rate is high. Therefore, drugs that cause disease remission in patients are expected to drive the growth of the market significantly. Further, the report states that the high cost of treatments is a major factor that restricts the growth of the market. Drugs for treatment of the cancer are expensive and hence, get poor response from patients. Hospital costs add to the cost of treatment. The co-morbidities associated with small cell lung cancer also need to be treated, which increases the cost of treatment. Key Vendors - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Oncology Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/k9...small_cell
ZIOP: 10.81 (-0.39), GSK: 46.59 (+0.28), BMY: 65.80 (-0.20)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), XON: 44.10 (-0.91), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06)
Why Shares Intrexon Corp are Skyrocketing Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 30, 11:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Intrexon Corp surged higher...
ZIOP: 10.81 (-0.39), XON: 44.10 (-0.91)
Ziopharm up 15% on Intrexon/Merck Serono deal
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:26AM CDT
ZIOP: 10.81 (-0.39)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 9.26 (+0.05), CRMD: 8.61 (-0.22), NCFT: 26.14 (+0.19), LEJU: 9.88 (-0.19), CTRX: 59.56 (+0.05), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), CNAT: 6.66 (-0.15), XON: 44.10 (-0.91), BBEP: 6.23 (-0.06), ADMP: 4.83 (+0.07), CLDN: 13.68 (-0.26), ASPX: 100.88 (-0.01), HPTX: 45.97 (-0.11), GENE: 4.70 (-0.13), SYN: 2.33 (+0.01), ICEL: 16.48 (-0.02), HZNP: 31.75 (+0.97), OHRP: 2.94 (+0.12), SFUN: 8.04 (-0.52), CNET: 1.64 (+0.04)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 10.81 (-0.39), MRK: 57.60 (+0.09), XON: 44.10 (-0.91)
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 445.10 (+55.11), ZIOP: 10.81 (-0.39), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98), INXN: 31.78 (+0.29), TLT: 129.07 (+0.80), TBT: 42.60 (-0.54), LEN: 47.19 (+0.47), SPY: 211.65 (+0.49), QQQ: 110.54 (+1.48), XHB: 35.95 (+0.60), P: 18.37 (+0.66), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), PHM: 20.12 (+0.15), DIA: 180.54 (+0.17), ITB: 26.98 (+0.31), JUNO: 56.66 (-1.06), IWM: 125.86 (-0.42), KBH: 14.88 (+0.11), AAPL: 130.28 (+0.61), ZU: 13.59 (+0.30), BABA: 84.57 (+2.29)
3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.81 (-0.39), ESPR: 104.60 (-4.29), NVAX: 8.58 (-0.07), PFE: 35.27 (-0.09), XON: 44.10 (-0.91)
Why Ziopharm Oncology, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 1:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology sank by...
ZIOP: 10.81 (-0.39), KITE: 60.58 (-0.35), XON: 44.10 (-0.91), JUNO: 56.66 (-1.06)
Today's Dead Cat Bounce Stock: ZIOPHARM Oncology (ZIOP)
at The Street - Tue Apr 21, 9:47AM CDT
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate
ZIOP: 10.81 (-0.39)
TissueGene, Inc. Hires Robert Newman as Chief Operating Officer
PR Newswire - Tue Apr 21, 8:25AM CDT
TissueGene, Inc. a clinical-stage biopharmaceutical company focused on developing novel regenerative therapies in the field of cell therapy, today announced the appointment of Robert A Newman to the position of Chief Operating Officer. Mr. Newman was most recently Senior Vice President, Manufacturing, Program Management & Clinical Operations at ZIOPHARM Oncology, a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies in the cancer treatment field. Mr. Newman is an accomplished bio-pharmaceutical executive who will oversee clinical operations, manufacturing, research & development, business development and regulatory affairs as TissueGene enters pivotal phase 3 trials for its lead cell-based gene therapy asset, TG-C for the treatment of late-stage osteoarthritis of the knee.
ZIOP: 10.81 (-0.39)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.81 (-0.39), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Ziopharm Oncology (ZIOP) Stock Falls Today on Mediocre Solid Tumor Therapy Data
at The Street - Mon Apr 20, 2:18PM CDT
Shares of Ziopharm Oncology (ZIOP) were down in afternoon trading Monday after so-called CAR-T cellular therapies for solid tumors showed mediocre results at a conference on Sunday.
ZIOP: 10.81 (-0.39)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06)
Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 81.59 (+0.36), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), LMT: 195.37 (-1.83), BX: 41.41 (+0.42), EMES: 44.65 (-5.95), NOC: 161.78 (-1.05), TGTX: 16.23 (-0.18), SFL: 15.63 (-0.01), FRT: 140.42 (+0.15), KKR: 23.39 (-0.15), O: 49.37 (-0.02), VTR: 72.82 (-0.24), PBR: 9.99 (+0.59), RDS.B: 63.67 (-0.07), RDS.A: 62.76 (-0.20), EOG: 96.72 (-1.55), RCPT: 169.88 (-1.26), NAO: 9.77 (-0.26), OA: 72.91 (-1.33), RGR: 56.18 (-0.03), UNP: 107.51 (-0.61), STO: 19.88 (+0.02)
Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm
at The Street - Thu Apr 02, 4:57AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ZIOP: 10.81 (-0.39), NWBO: 8.47 (-0.15), XON: 44.10 (-0.91)
Global Small Cell Lung Cancer Therapeutics Market 2015-2019 with Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi & ZIOPHARM Oncology Dominating
PR Newswire Europe - Wed Apr 01, 1:02PM CDT
DUBLIN, April 1, 2015 /PRNewswire/ --
ZIOP: 10.81 (-0.39), GSK: 46.59 (+0.28), BMY: 65.80 (-0.20)
ZIOPHARM Oncology (ZIOP) Highlighted As Weak On High Volume
at The Street - Wed Apr 01, 9:02AM CDT
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a weak on high relative volume candidate
ZIOP: 10.81 (-0.39)
Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 5:26PM CDT
Intrexon Corporation (XON) and Merck KGaA announced the signing of an agreement to develop and commercialize cancer therapies based on CAR-T platform.
CYTK: 7.25 (-0.18), ZIOP: 10.81 (-0.39), XON: 44.10 (-0.91)
Global Small Cell Lung Cancer Therapeutics Market 2015-2019
M2 - Tue Mar 31, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9z3pb/global_small_cell) has announced the addition of the "Global Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.6% over the period 2014-2019 The report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The strategic alliances among vendors are an important trend being witnessed in the market. These are expected to give these market players a competitive edge over the others. The companies can leverage their strengths, which is expected to prove mutually beneficial. According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Small cell lung cancer advances very fast, and the detection rate is low at the localized stage. Current treatment options cannot cure the disease; hence, the mortality rate is high. Therefore, drugs that cause disease remission in patients are expected to drive the growth of the market significantly. Further, the report states that the high cost of treatments is a major factor that restricts the growth of the market. Drugs for treatment of the cancer are expensive and hence, get poor response from patients. Hospital costs add to the cost of treatment. The co-morbidities associated with small cell lung cancer also need to be treated, which increases the cost of treatment. Key Vendors - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Oncology Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/k9...small_cell
ZIOP: 10.81 (-0.39), GSK: 46.59 (+0.28), BMY: 65.80 (-0.20)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), XON: 44.10 (-0.91), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06)
Why Shares Intrexon Corp are Skyrocketing Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 30, 11:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Intrexon Corp surged higher...
ZIOP: 10.81 (-0.39), XON: 44.10 (-0.91)
Ziopharm up 15% on Intrexon/Merck Serono deal
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:26AM CDT
ZIOP: 10.81 (-0.39)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 9.26 (+0.05), CRMD: 8.61 (-0.22), NCFT: 26.14 (+0.19), LEJU: 9.88 (-0.19), CTRX: 59.56 (+0.05), ZIOP: 10.81 (-0.39), ADXS: 23.34 (-0.27), CNAT: 6.66 (-0.15), XON: 44.10 (-0.91), BBEP: 6.23 (-0.06), ADMP: 4.83 (+0.07), CLDN: 13.68 (-0.26), ASPX: 100.88 (-0.01), HPTX: 45.97 (-0.11), GENE: 4.70 (-0.13), SYN: 2.33 (+0.01), ICEL: 16.48 (-0.02), HZNP: 31.75 (+0.97), OHRP: 2.94 (+0.12), SFUN: 8.04 (-0.52), CNET: 1.64 (+0.04)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 10.81 (-0.39), MRK: 57.60 (+0.09), XON: 44.10 (-0.91)
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 445.10 (+55.11), ZIOP: 10.81 (-0.39), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98), INXN: 31.78 (+0.29), TLT: 129.07 (+0.80), TBT: 42.60 (-0.54), LEN: 47.19 (+0.47), SPY: 211.65 (+0.49), QQQ: 110.54 (+1.48), XHB: 35.95 (+0.60), P: 18.37 (+0.66), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), PHM: 20.12 (+0.15), DIA: 180.54 (+0.17), ITB: 26.98 (+0.31), JUNO: 56.66 (-1.06), IWM: 125.86 (-0.42), KBH: 14.88 (+0.11), AAPL: 130.28 (+0.61), ZU: 13.59 (+0.30), BABA: 84.57 (+2.29)
3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.81 (-0.39), ESPR: 104.60 (-4.29), NVAX: 8.58 (-0.07), PFE: 35.27 (-0.09), XON: 44.10 (-0.91)
Why Ziopharm Oncology, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 1:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology sank by...
ZIOP: 10.81 (-0.39), KITE: 60.58 (-0.35), XON: 44.10 (-0.91), JUNO: 56.66 (-1.06)
